BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Gilead Sciences
Bristol-Myers Squibb
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Pfizer
Merck Sharp & Dohme LLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Incyte Corporation
Verastem, Inc.
Hoffmann-La Roche
UNICANCER
Pfizer
AstraZeneca
AstraZeneca
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
AstraZeneca
University of Rochester
Merck Sharp & Dohme LLC
Gilead Sciences
Eikon Therapeutics
Hoffmann-La Roche
NRG Oncology
University of Illinois at Chicago
University of Utah
Shanghai Henlius Biotech
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sichuan University
Merck Sharp & Dohme LLC
University of Southern California
Bristol-Myers Squibb
ImmunityBio, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Genelux Corporation
Merck Sharp & Dohme LLC
AbbVie
University of Iowa
Trishula Therapeutics, Inc.
Iovance Biotherapeutics, Inc.
Hummingbird Bioscience
Amgen
UNC Lineberger Comprehensive Cancer Center
EpicentRx, Inc.
Tianjin Medical University Cancer Institute and Hospital
ImmunityBio, Inc.
Shanghai Pulmonary Hospital, Shanghai, China
Phanes Therapeutics
Merck Sharp & Dohme LLC
Vanderbilt-Ingram Cancer Center